Novo, Deen agree to suspend their relationship

Share this article:
Victoza effort featuring Southern cuisine queen Deen draws flak
Victoza effort featuring Southern cuisine queen Deen draws flak

While the number of lost partnerships continue to pile up around the Paula Deen empire—Caesar's Entertainment, Food Network, Smithfield Hams and, according to the Associated Press, Wal-Mart—Novo Nordisk is splitting the difference, suspending, but not ending its endorsement deal with Southern cook.

Novo tells MM&M the suspension is an open-ended one and the company is going to “give her time to get everything together.”

Deen's reputation and sponsorship business has imploded since last week, when a deposition in which she admitted to using a racial epithet coursed through the Internet. Her handling of the situation has been a combination of acknowledging she used a hurtful word, that she was who she was, and that, as she told Today's Matt Lauer, that she does not know what others consider offensive.

Deen's relationship with Novo started on shaky ground last year. The restaurateur and home cook whose fame had become synonymous with butter and sugar (and as of two weeks ago, literally linked to fat), only revealed her diabetes status when she started touting Victoza. Deen said she had known she was a diabetic for three years.

Novo emphasized that the relationship is not severed and the cooling-off period was a mutual decision. “Novo Nordisk would like to acknowledge Paula's involvement in our Diabetes in a New Light campaign, where she has helped make many people aware of type 2 diabetes and the lifestyle changes needed to control this serious disease,” the company said in a statement.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...